Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert

$FLR
$GM
$LLY
$STLA
Military/Government/Technical
Industrials
Auto Manufacturing
Consumer Discretionary
Get the next $FLR alert in real time by email

Thanks largely to some blockbuster projects, the value of industrial construction presently underway in Indiana and tracked by Industrial Info exceeds $39 billion. The projects cover a range of sectors from pharmaceutical-biotech projects to cutting-edge data centers.

By far the largest project presently underway in the state is pharmaceutical giant Eli Lilly and Company's ((LLY) (Indianapolis, Indiana) expansion of its campus in Lebanon, about 30 miles from Lilly's headquarters in Indianapolis. The project broke ground in the summer of 2023, with engineering, procurement and construction (EPC) firm Fluor Corporation ((FLR) (Irving, Texas) leading the work.

Other multibillion projects in the state involve the automotive sector, specifically the manufacture of the batteries that power electric vehicles (EVs). Both General Motors Company ((GM) (GM) (Detroit, Michigan) and Stellantis NV ((STLA) (Hoofddorp, Netherlands) are constructing battery plants in the state.

Click here to view the rest of this article.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 Trillion (USD).

Get the next $FLR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FLR
$GM
$LLY
$STLA

CompanyDatePrice TargetRatingAnalyst
1/21/2025$60.00Hold → Buy
Deutsche Bank
12/18/2024$54.00 → $58.00Outperform → Neutral
Robert W. Baird
12/11/2024$58.00Buy → Hold
HSBC Securities
12/10/2024$997.00Buy
BofA Securities
12/10/2024$46.00 → $54.00Underweight → Equal-Weight
Morgan Stanley
11/15/2024$1000.00Outperform
Wolfe Research
11/11/2024In-line
Evercore ISI
10/22/2024$52.00 → $65.00Neutral → Buy
Citigroup
More analyst ratings

$FLR
$GM
$LLY
$STLA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Jeep® Brand Unveils New Limited Edition 2025 Wrangler 4xe Backcountry

    Created for Jeep® customers who appreciate tech, features and refinement of the Wrangler 4xe Sahara, but crave next-level off-road capabilities    AUBURN HILLS, Mich., Feb. 19, 2025 /PRNewswire/ -- New limited edition 2025 Jeep Wrangler 4xe Backcountry enhances and enriches Wrangler 4xe Sahara by combining new standard comfort features, like a nine-speaker Alpine audio system and the 4xe-exclusive Jeep Power Box to power accessories, with capability enhancements, such as aggressive 32-inch General Grabber A/T tires and front and rear steel bumpers, along with a body-color hard

    $STLA
    Auto Manufacturing
    Consumer Discretionary
  • Lilly to participate in TD Cowen's 45th Annual Health Care Conference

    INDIANAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology, will take part in a fireside chat at 1:50 p.m., Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering li

    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Fluor Reports Fourth Quarter and Full Year 2024 Results

    Full year new awards of $15.1 billion; 85% reimbursable Ending backlog of $28.5 billion; 79% reimbursable Strong operating cash flow for 2024 of $828 million; highest OCF generation since 2015 Q4 share repurchases of $125 million; $300 million planned for 2025 $1.6 billion gain recognized from deconsolidation of NuScale investment Fluor Corporation (NYSE:FLR) announced financial results for its year ended December 31, 2024. Revenue for 2024 was $16.3 billion and net income attributable to Fluor was $2.1 billion, or $12.30 per diluted share, reflecting the deconsolidation and subsequent remeasurement of Fluor's investment in NuScale. Consolidated segment profit1 for the year was $

    $FLR
    Military/Government/Technical
    Industrials

$FLR
$GM
$LLY
$STLA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FLR
$GM
$LLY
$STLA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FLR
$GM
$LLY
$STLA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FLR
$GM
$LLY
$STLA
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FLR
$GM
$LLY
$STLA
Leadership Updates

Live Leadership Updates

See more
  • Fluor Announces Appointment of Jim Breuer as CEO; David E. Constable to Transition to Executive Chairman

    Fluor Corporation (NYSE:FLR) announced today that its Board of Directors has appointed Chief Operating Officer (COO), Jim Breuer, as Chief Executive Officer (CEO), effective May 1, 2025. David E. Constable, Fluor's current Chairman and CEO, will transition into the role of Executive Chairman on the same date, ensuring continuity of leadership and strategic direction of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218694498/en/Jim Breuer named Fluor Chief Executive Officer, effective May 1, 2025. (Photo: Business Wire) Breuer has held the role of COO since 2024, driving a more holistic approach to Fluor's markets

    $FLR
    Military/Government/Technical
    Industrials
  • Tutor Perini Announces Appointment of Gary Smalley as its New CEO

    -- Ronald Tutor Will Serve as Executive Chairman of the Board through 2026 -- Tutor Perini Corporation (NYSE:TPC) (the "Company"), a leading civil, building and specialty construction company, announced today that Gary Smalley has become the Company's Chief Executive Officer and a member of its Board of Directors. Mr. Smalley, formerly President, succeeds Ronald N. Tutor who has transitioned to the role of Executive Chairman of Tutor Perini's Board of Directors after serving as Chairman and CEO since 2008. Prior to today's announcement, Mr. Smalley served as President of Tutor Perini since November 2023, when the Company announced its formal succession plan under which he would succeed

    $FLR
    $TPC
    Military/Government/Technical
    Industrials
    General Bldg Contractors - Nonresidential Bldgs
    Consumer Discretionary
  • Stellantis Organizational Announcement

    Stellantis Organizational Announcement AMSTERDAM, December 2, 2024 – The process to appoint the new permanent Chief Executive Officer is well under way, managed by a Special Committee of the Board, and will be concluded within the first half of 2025. While the appointment of the new CEO is concluded the following organization is implemented with immediate effect. The Interim Executive Committee ("IEC") will be responsible for the direction and oversight of the Company on behalf of the Board of Directors. The IEC will be chaired by John ELKANN. The committee shall be made up of the Chairman together with the following executives whose responsibilities are as follows: Xavier CHÉREAU        

    $STLA
    Auto Manufacturing
    Consumer Discretionary

$FLR
$GM
$LLY
$STLA
Financials

Live finance-specific insights

See more
  • Fluor Reports Fourth Quarter and Full Year 2024 Results

    Full year new awards of $15.1 billion; 85% reimbursable Ending backlog of $28.5 billion; 79% reimbursable Strong operating cash flow for 2024 of $828 million; highest OCF generation since 2015 Q4 share repurchases of $125 million; $300 million planned for 2025 $1.6 billion gain recognized from deconsolidation of NuScale investment Fluor Corporation (NYSE:FLR) announced financial results for its year ended December 31, 2024. Revenue for 2024 was $16.3 billion and net income attributable to Fluor was $2.1 billion, or $12.30 per diluted share, reflecting the deconsolidation and subsequent remeasurement of Fluor's investment in NuScale. Consolidated segment profit1 for the year was $

    $FLR
    Military/Government/Technical
    Industrials
  • Lilly reports full Q4 2024 financial results and provides 2025 guidance

    Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023.Pipeline progress included the approval of Zepbound in the U.S. for moderate-to-severe obstructive sleep apnea in adults with obesity and the approval of Omvoh in the U.S. for moderately to severely active Crohn's disease.Notable recent events include the pending acquisition of Scorpion Therapeutics, Inc's mutant-selective PI3Kα inhibitor program. Q4 2024 EPS increased 102% to $4.88 on a reported basis, and 114% to $5.32 on a non-GAAP basis, both inclusive of $0.19 of acquired IPR&D charges. 2025 guidance issued with revenue in the ran

    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Stellantis to Announce Full Year 2024 Results on February 26

    Stellantis to Announce Full Year 2024 Results on February 26 AMSTERDAM, February 5, 2025 - Stellantis N.V. announced today that its Full Year 2024 Results will be released on Wednesday, February 26, 2025. A live webcast and conference call of the Full Year 2024 Results will begin at 2:00 p.m. CET / 8:00 a.m. EST on Wednesday, February 26, 2025. The related press release and presentation material are expected to be posted under the Investors section of the Stellantis corporate website at www.stellantis.com at approximately 8:00 a.m. CET / 2:00 a.m. EST on Wednesday, February 26, 2025. Details for accessing this presentation are available under the Investors section of the Stellantis corp

    $STLA
    Auto Manufacturing
    Consumer Discretionary

$FLR
$GM
$LLY
$STLA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more